#Singapore #Haier Biomedical #ISPE Singapore #Bio-storage Solutions

Haier Biomedical Showcases Automated Solutions at ISPE Singapore 2026

Haier Biomedical, a prominent player in the biopharmaceutical infrastructure sector, recently made waves at the ISPE Singapore Conference and Exhibition 2026, held from August 20 to 21. During this renowned event focused on pharmaceutical engineering, the company unveiled its robust portfolio of automated and digital solutions designed for key workflows in pharmaceutical research and development (R&D), production, and quality control. What stood out most during the exhibition was the introduction of their automated storage solution that operates at a chilling -80 °C, marking its international debut. Alongside this, the pilot lyophilizer was also showcased, emphasizing Haier Biomedical's commitment to leading the charge in low-temperature storage solutions.

Innovative Storage Solutions

The highlight of the exhibition was undoubtedly the automated storage solution aimed at pharmaceutical companies and research organizations managing high-value samples at ultra-low temperatures. This advanced system combines automated sample storage with intelligent sample management, significantly enhancing workflow efficiency and traceability. The pilot lyophilizer plays a crucial role in linking laboratory research with subsequent manufacturing stages, thus supporting pharmaceutical process development and pilot-scale lyophilization. Together, these two products meet the complementary needs of sample management, process development, and pilot-scale production.

Moreover, Haier Biomedical's features included an intelligent RFID ULT storage solution designed to connect physical samples with digital records throughout the storage workflow. Each sample is assigned a unique identity via RFID tags, while specialized antennas and readers within the compartments gather data without the need for visual scanning. This innovative software links each sample to its location and movement history, creating structured records of both entries and exits.

The configurable system accommodates various sample formats, including bottles, bags, tubes, and cryovials, with tailored storage interfaces provided by shelves, trays, and custom supports. By connecting sample identity, location, movement, and storage conditions, the platform aims to minimize manual searching and inventory reconciliation while enhancing visibility and chain of custody during quality control, storage, and supply chain operations.

Meeting Evolving Industry Needs

As pharmaceutical operations become increasingly automated, data-driven, and quality-centric, customers are starting to require more than just standalone equipment. They are looking for integrated workflows that link samples, devices, and data across R&D, production, and quality control. This demand was reflected in Haier Biomedical's expanded offerings, which encompass automation systems, ULT freezers, refrigerated centrifuges, freeze-thaw systems, and other technologies supporting pharmaceutical workflows from R&D and production to quality control laboratories and cold storage.

Recently, the company reported a 23% year-over-year increase in revenue related to pharmaceutical clients, with lab solutions revenue growing by 19%. Furthermore, AI-related business contributed to 18% of their total revenue, marking a 3 percentage point increase from 2025.

By tailoring its products and technologies to meet local regulations, infrastructure, and customer needs, Haier Biomedical aims to assist its clients in building smarter, connected, and scalable pharmaceutical R&D and production systems. As the company emphasizes innovation in storage solutions and advanced technology, it cements its position as a vital contributor to the evolution of biopharmaceutical infrastructure.

For more details, visit Haier Biomedical's Official Website.